Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Shanghai, China, Aug. 30, 2021 – Shanghai MicroPort EP MedTech Co., Ltd (MicroPort EP) and Stereotaxis (NYSE: STXS) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.
The agreement brings together MicroPort EP's commercial and product leadership in China's electrophysiology market with Stereotaxis’advanced Robotic Magnetic Navigation technology. As part of the collaboration, MicroPort EP will become the exclusive distributor of Robotic Magnetic Navigation technology for electrophysiology in China.
Stereotaxis, established in 1990, is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis launched the world's first Robotic Magnetic Navigation system Niobe® in 2003, and the updated version Genesis RMN® system got FDA approval in 2020. Core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, China, Japan, Canada, and elsewhere.
MicroPort EP will pursue regulatory approvals for Stereotaxis’latest innovations including the Genesis RMN® system and proprietary magnetic ablation catheter. The companies will integrate Stereotaxis’ robotic systems with MicroPort EP's ColumbusTM mapping system, allowing physicians to benefit from the combination of both technologies. Both parties will also work together to develop a family of cardiac ablation and diagnostic catheters.
“I am very excited by the promise of this collaboration,” said Prof. Jin Qi of Ruijin Hospital. “Having completed nearly 2,000 robotic ablations, I deeply understand the value of robotic technology and appreciate how this partnership will expand broad access to these benefits for hospitals, physicians and their patients across China.”
The agreement further advances MicroPort EP's pivotal role in China's electrophysiology market by enabling it to develop and offer a highly differentiated product portfolio. The agreement builds upon the increasing interest and adoption Stereotaxis has experienced in China, is expected to significantly accelerate adoption, and supports Stereotaxis's strategy of building a robust open ecosystem of therapeutic and diagnostic technologies used with Robotic Magnetic Navigation.
"Stereotaxis and MicroPort EP are delighted to enter into this strategic collaboration and are confident it will benefit both companies along with the electrophysiologists and arrhythmia patients we serve," said David Fischel, CEO of Stereotaxis and Dr.Yiyong Sun, President of MicroPort EP. "We look forward to providing China's electrophysiology community with highly innovative and differentiated products that leverage Robotic Magnetic Navigation technology. This will both strengthen the importance of robotics and reinforce the key role of MicroPort EP in this rapidly growing and underserved market.”
